The AstraZeneca COVID vaccine is now available to Australians over 50. Here's what you need to know before you roll up your sleeve.
Academic rigor, journalistic flair
Articles on Oxford-AstraZeneca vaccine
Displaying 1 - 20 of 51 articles
Licensing agreements between pharmaceutical companies and the Medicines Patent Pool, in cooperation with the WHO, could accelerate access to doses for the poorest countries.
The R21 vaccine protected three-quarters of children against malaria in trials.
Britain moves to protect itself from the B1617 variant, which vaccines may be less effective against.
Current assessments of the risk of blood clots are still uncertain.
Side effects generally indicate a natural immune response and will resolve in a few days.
Both the AstraZeneca and Johnson & Johnson vaccines are now being investigated for links to rare blood disorders.
European regulators are investigating a possible link between the vaccine and a second rare blood disorder.
A vaccine expert breaks down everything you need to know about the Novavax vaccine.
With changing recommendations about AstraZeneca's COVID-19 vaccine making headlines, many people have questions about its use.
The mechanisms behind vaccine-related and pill-related clots are quite different.
How do we reasonably and accurately balance the risks of the AstraZeneca vaccine against the benefits? Conceptualising risk can be tricky, but the government's latest advice is sensible.
This shift in focus away from AstraZeneca to the Pfizer vaccine has serious impacts on the timing of the rollout and public confidence in the AstraZeneca vaccine.
The UK's proposal to give under-30s other vaccines shouldn't be too disruptive, but in Europe, greater restrictions look likely.
All vaccines and medications come with risks. But the risks of delaying vaccination are far higher.
Scientists have called it "vaccine-induced prothrombotic immune thrombocytopenia", or VIPIT. The condition is characterised by a shortage of platelets in the blood.
We need to stop relying on small GP clinics and urgently move towards using mass vaccination hubs like stadiums, schools and parks.
Exports of the vaccine continue to be a point of contention between the EU and UK, while newly released US trial results are quickly amended.
These results can help allay previous concerns in Europe about a lack of trial data for older people.
AstraZeneca just announced results from its US-based trial. It found the vaccine to be 79% effective and safe for use, despite recent concerns around reports of blood clots.
Top contributors
-
Professor of Medicine, University of East Anglia
-
Senior Research Fellow in Global Health, University of Southampton
-
Professor in Global Public Health and Director of the Mitchell Institute, Victoria University
-
Reader in Clinical Pharmacy and Drug Safety, University of Birmingham
-
Professor of Immunology and Associate Provost, Research Partnerships, Victoria University
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Senior Lecturer; MD, Victoria University
-
Senior Lecturer in Viral Immunology, University of Birmingham
-
Professor of Immunology, RMIT University
-
Postdoctoral Research Fellow, RMIT University
-
Assistant Professor, General Practice, Bond University
-
Visiting Professor in Biomedical Ethics, Murdoch Children's Research Institute; Distinguished Visiting Professor in Law, University of Melbourne; Uehiro Chair in Practical Ethics, University of Oxford
-
Professorial Fellow, University of Canberra
-
Associate professor, UNSW
-
Director of the Jenner Institute, University of Oxford
